Patents by Inventor Christopher J. Bond
Christopher J. Bond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230060292Abstract: Provided herein are cells, such as iNKT cells that include a split dual targeting chimeric antigen receptors (CARs), and methods of use. The split CARs are each linked to an invariant TCR alpha or TRC beta chain.Type: ApplicationFiled: July 25, 2022Publication date: March 2, 2023Inventor: Christopher J. Bond
-
Patent number: 10960088Abstract: Provided are macrocyclic compounds and iron or cobalt coordinated macrocyclic compounds. The compounds can be used as MRI contrast agents. Certain compounds are redox active and can be used to assess the biological redox status of a sample.Type: GrantFiled: September 12, 2014Date of Patent: March 30, 2021Assignees: The Research Foundation for The State University of New York, Health Research, Inc.Inventors: Janet R. Morrow, Pavel B. Tsitovich, Sarina J. Dorazio, Abiola O. Olatunde, Joseph A. Spernyak, Patrick Burns, Eric M. Snyder, Christopher J. Bond
-
Patent number: 9873726Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: GrantFiled: July 14, 2016Date of Patent: January 23, 2018Assignee: ONCOMED PHARMACEUTICALS, INC.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Publication number: 20170267776Abstract: The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: ApplicationFiled: February 22, 2017Publication date: September 21, 2017Inventors: Austin L. GURNEY, Christopher J. Bond
-
Patent number: 9598497Abstract: The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: GrantFiled: September 30, 2015Date of Patent: March 21, 2017Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Christopher J. Bond
-
Publication number: 20170002054Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: ApplicationFiled: July 14, 2016Publication date: January 5, 2017Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Alexandra L.L. Lazetic, Christopher J. Bond
-
Patent number: 9422546Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: GrantFiled: April 3, 2015Date of Patent: August 23, 2016Assignee: ONCOMED PHARMACEUTICALS, INC.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Publication number: 20160228581Abstract: Provided are macrocyclic compounds and iron or cobalt coordinated macrocyclic compounds. The compounds can be used as MRI contrast agents. Certain compounds are redox active and can be used to assess the biological redox status of a sample.Type: ApplicationFiled: September 12, 2014Publication date: August 11, 2016Inventors: Janet R. MORROW, Pavel B. TSITOVICH, Sarina J. DORAZIO, Abiola O. OLATUNDE, Joseph A. SPERNYAK, Patrick BURNS, Eric M. SNYDER, Christopher J. BOND
-
Publication number: 20160108130Abstract: The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: ApplicationFiled: September 30, 2015Publication date: April 21, 2016Inventors: Austin L. GURNEY, Christopher J. BOND
-
Patent number: 9181333Abstract: The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: GrantFiled: July 12, 2013Date of Patent: November 10, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Christopher J. Bond
-
Publication number: 20150315565Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: ApplicationFiled: April 3, 2015Publication date: November 5, 2015Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Alexandra L. L. Lazetic, Christopher J. Bond
-
Patent number: 9023621Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: GrantFiled: September 6, 2013Date of Patent: May 5, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Patent number: 8945878Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: GrantFiled: September 6, 2013Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Publication number: 20140017253Abstract: The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: ApplicationFiled: July 12, 2013Publication date: January 16, 2014Applicant: ONCOMED PHARMACEUTICALS, INCInventors: AUSTIN L. GURNEY, CHRISTOPHER J. BOND
-
Publication number: 20140005077Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: ApplicationFiled: September 6, 2013Publication date: January 2, 2014Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Alexandra L.L. Lazetic, Christopher J. Bond
-
Publication number: 20140005076Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: ApplicationFiled: September 6, 2013Publication date: January 2, 2014Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Alexandra L.L. Lazetic, Christopher J. Bond
-
Patent number: 8551715Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: GrantFiled: February 11, 2011Date of Patent: October 8, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Publication number: 20110287979Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: ApplicationFiled: February 11, 2011Publication date: November 24, 2011Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Patent number: 7785903Abstract: The invention provides polypeptides comprising a variant heavy chain variable framework domain (VFR). In some embodiments, the amino acids defining the VFR form a loop of an antigen binding pocket. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR. The polypeptide may optionally comprise one or more complementary determining regions (CDRs) of antibody variable domains. In an embodiment, the polypeptide is a variable domain of a monobody and has a variant VFR and one or more variant CDRs. Libraries of polypeptides that include a plurality of different antibody variable domains generated by creating diversity in a VFR, and optionally, one or more CDRs are provided and may be used as a source for identifying novel antigen binding polypeptides that can be used therapeutically or as reagents. The invention also provides fusion polypeptides, compositions, and methods for generating and using the polypeptides and libraries.Type: GrantFiled: April 8, 2005Date of Patent: August 31, 2010Assignee: Genentech, Inc.Inventors: Christopher J. Bond, Sachdev Sidhu